A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

Peer Review reports

Original Submission
20 Oct 2022	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
6 Jan 2023	Reviewed	Reviewer Report
22 Jan 2023	Reviewed	Reviewer Report - Giuseppe Sileno
5 Feb 2023	Author responded	Author comments - Tray Brown
Resubmission - Version 4
5 Feb 2023	Submitted	Manuscript version 4
Publishing
15 Feb 2023	Editorially accepted
9 Mar 2023	Article published	10.1186/s12882-023-03088-3

Back to article page